Interaction Check

This page cannot be displayed because your browser has been configured to disable JavaScript, also known as "Active Scripting".Please change your settings and refresh the page.

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

MultiCheck Results - 4 Interactions

Avoid/Use Alternative
diclofenac epolamine topical (generic) + olmesartan medoxomil/hydrochlorothiazide (generic)
Avoid/Use Alternative diclofenac topical + olmesartan medoxomil consider alternative or monitor potassium, renal fxn, BP: combo may incr. risk of renal impairment, hyperkalemia; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects) Monitor/Modify Tx diclofenac topical + hydrochlorothiazide monitor BP, renal fxn: combo may incr. risk of renal impairment; may decr. hydrochlorothiazide efficacy (additive effects; antagonistic effects)
Monitor/Modify Tx
Antara (fenofibrate micronized) + diclofenac epolamine topical (generic)
Monitor/Modify Tx fenofibrate + diclofenac topical monitor thrombosis s/sx; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of thromboembolism (additive effects)
Fluzone (influenza A and B trivalent vaccine, inactivated (IIV3)) + Ilumya (tildrakizumab-asmn) (tildrakizumab)
Monitor/Modify Tx influenza vaccine + tildrakizumab if possible, vaccinate at least 2wk before starting tildrakizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)
Additional Considerations
tildrakizumab in Ilumya (tildrakizumab-asmn)
caution advised w/ narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx w/ immune modulators may reverse this effect, resulting in altered levels of concomitant drugs